SeaStar Medical (NASDAQ:ICU) and Organon & Co. (NYSE:OGN) Head to Head Analysis

Organon & Co. (NYSE:OGN) and SeaStar Medical (NASDAQ:ICU) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Risk & Volatility

Organon & Co. has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1, indicating that its share price is 200% less volatile than the S&P 500.

Profitability

This table compares Organon & Co. and SeaStar Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.01%	123.06%	6.68%
SeaStar Medical	-1,551.08%	-414.50%	-151.13%

Insider and Institutional Ownership

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are held by institutional investors. 1.4% of Organon & Co. shares are held by company insiders. Comparatively, 0.7% of SeaStar Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Organon & Co. and SeaStar Medical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22 billion	0.31	$187.00 million	$0.71	10.57
SeaStar Medical	$140,000.00	66.87	-$24.83 million	($16.50)	-0.15

Organon & Co. has higher revenue and earnings than SeaStar Medical. SeaStar Medical is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Organon & Co. and SeaStar Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	5	1	0	1	1.57
SeaStar Medical	1	0	0	0	1.00

Organon & Co. currently has a consensus price target of $8.50, indicating a potential upside of 13.26%. SeaStar Medical has a consensus price target of $6.00, indicating a potential upside of 142.91%. Given SeaStar Medical’s higher possible upside, analysts plainly believe SeaStar Medical is more favorable than Organon & Co..

Summary

Organon & Co. beats SeaStar Medical on 12 of the 14 factors compared between the two stocks.

About Organon & Co.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.